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Abstract
A novel ultra-performance liquid chromatography with UV detector technique was established for simultaneous determination of
two antidiabetic drugs, dapagliflozin (DAPA) and metformin (MET), followed by a stress degradation study. Main degradation
product was chromatographically separated and precisely characterized via LC-MS/MS. Chromatographic separation done on
a Symmetry® Acclaim™ RSLC 120 C18 column (100 mm, 2.1 mm, 2.2 µm), column temperature was maintained at 60 °C.
Mobile phase was a mixture of potassium dihydrogen phosphate buffer, pH (3.5)—acetonitrile (50:50, v/v) at flow rate of 0.4 mL/
min. The method has displayed an adequate detection at concentration ranges of 1–50 µg/mL for dapagliflozin propanediol
monohydrate and 0.5–100 µg/mL for metformin hydrochloride. DAPA was then exposed to different stress conditions include
alkaline, acidic, oxidative and ultraviolet light. A study of the degradation kinetics in alkaline medium for DAPA has proved that
the degradation follows a pseudo-first-order reaction. The proposed method was effectively applied for the analysis of laboratory
prepared mixtures as well as a combined pharmaceutical formulation with 1:200 ratio of DAPA: MET. No significant difference
was found regarding accuracy and precision upon statistical comparison between the obtained results and those of the reported
method. Validation was conducted in compliance with the ICH guidelines proving that method is selective, linear, precise and
accurate. The simplicity and sensitivity of this method allows its use in the quality control tests of the two cited drugs.
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Introduction
Metformin (MET) and dapagliflozin (DAPA) Fig. 1; the
first is best to be described as efficient anti-hyperglycemia
legacy agent, comes along with a recently approved and
clinically validated medication, dapagliflozin.
Generally metformin is the most accepted first-line
treatment in type 2 diabetes mellitus patients. It improves
peripheral and hepatic sensitivity to insulin, reduces liver
gluconeogenesis and enhances the utilization of glucose
by peripheral tissues [1].
DAPA belongs to a new antidiabetic class which is
sodium glucose co-transporter 2 (SGLT2) inhibitors. In
kidneys, glucose is reabsorbed into the proximal tubule
through the sodium-coupled glucose co-transporter

Fig. 1  Dapagliflozin (a) and Metformin (b) structures

(SGLT2). This promotes urinary excretion of glucose and
results in lowering of blood glucose level. Administration
of agents (e.g., DAPA) that inhibits SGLT2 transporter
have shown to be associated with improvement in hyperglycaemia without clinically persistent electrolytes disturbances. This shows why administration of DAPA alone
or in combination is effective and safe as a combination
treatment for hyperglycaemia [2].
Referring to the literature review; sparse methods were
proclaimed [3–7] for concentration assurance of DAPA
and MET together in pharmaceutical preparations or in
laboratory prepared mixtures. Other few methods were
found for determination of DAPA alone, either in dosage
form [8–12] or in rat plasma [13]. On the contrary, various analysis methodologies were developed for investigation of MET using both spectrophotometry and chromatographic techniques with many degradation and kinetic
studies [13–34]. Owing to the many reported methods of
metformin degradation, the scope of the presented work
was out of this part.
This work aimed to achieve the first UHPLC method
for concurrent separation and concentration quantification
of DAPA and MET in laboratory prepared mixtures and
in pharmaceutical dosage form with very low ratio 1:200.
This is done through spiking and standard addition technique followed by applying the chromatographic method.
It is worth to mention the added value of this proposed
study over the previous work on this combination. This is
the only UHPLC–UV method for simultaneous determination of DAPA and MET in one chromatogram via applying

Table 1  Comparison between the chromatographic conditions used for separation of metformin and dapagliflozin in different reported HPLC–
UV methods and the proposed method
Method

Column

Mobile phase

Flow rate

Proposed method

Symmetry® Acclaim™ RSLC 120
C18 column (100 mm × 2.1 mm,
2.2 µm)

Phosphate buffer: acetonitrile
(pH 3.5)
(50:50, v/v)

Yunoos et al. [5]

Hypersil BDS-C18
(250 mm × 4.6 mm, 5 µm)

Trimethylamine :acetonitrile
(ph 6.8)
(50:50, v/v)

Shyamala. et al. [6]
Method

Hypersil BDS-C18 (250 × 4.6 mm,
5 µm)

Deepan et al. [7]
Method

Inspire-C18 (4.6 mm × 150 mm,
5 µm)

Phosphate buffer: methanol:
acetonitrile
(pH 6.5)
(50:30:20 v/v/v)
Phosphate buffer: acetonitrile
(pH 3.0)
(30:70, v/v)

0.4 ml/min 0.5 µg/mL to 100 µg/mL for metformin HCL
1 µg/mL to 50 µg/mL for dapagliflozin
1 ml/min
85 µg/mL to 510 µg/mL for metformin HCL
0.5 µg/mL to 3 µg/mL for dapagliflozin
1.0 ml/min 85 µg/mL to 510 µg/mL for metformin HCL
0.5 µg/mL to 3 µg/mL for dapagliflozin
1.0 ml/min 500–2500 µg/mL metformin HCL
5–25 µg/mL dapagliflozin
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Table 2  Regression and validation parameters for the determination
of the dapagliflozin and metformin by the proposed method
Parameters

DAPA

MET

Linearity range
Slope
Intercept
Correlation coefficient
Accuracy (mean ± SD)
LOD
LOQ
Precision (%RSD)
Repeatability
Intermediate precision
Specificity (mean ± SD)

1–50 µg mL−1
1.5216
0.3729
0.9999
99.72 ± 0.94
1.01 µg mL−1
3.08 µg mL−1
0.16

0.5–100 µg mL−1
1.3515
0.8154
0.9999
99.79 ± 0.51
0.93 µg mL−1
2.83 µg mL−1
1.5

1.77
99.81 ± 1.16

1.26
100.46 ± 1.54

spiking technique. In addition, this UHPLC study was
done using the least amount of phosphate solution besides
the least flow rate ever used which was 0.4 mL/min. The
advantages are shown in Tables 1 and 2 which present the
pervious methods found in the literature in comparison
with the proposed method. Moreover, this piece of work is
presenting stress degradation and a kinetic study for DAPA
as up to our knowledge; there is no reported kinetic study
for its degradation.
Aubry, Gu, Magnier et al. [13] have performed HPLC
method for detection of DAPA in plasma using LC–MS/
MS in rat plasma. They achieve lowest reported limit of
detection and quantification, yet mass detector is considered quiet expensive and less notorious; it may not be used
as regular method in quality control laboratories. Where’s
Aubry, Gu, Magnier et al. aimed to achieve detection in rat
plasma that in turn need a higher level of sensitivity, while
this UHPLC–UV was driven to perform regular quality
supervision of drug in raw or in tablet dosage form. Not to
mention that analytical methods utilizing UV detectors are
the most widely used in analytical chemistry laboratories.
In general, an UHPLC technique is more preferable than
ordinary HPLC method. Budget wise, an UHPLC method is
much more convenient as it is more fiscal, it consumes less
mobile phase over shorter periods. Furthermore, upon comparison with other reported methods, this proposed method
reveals major advantages in terms of shorter retention times,
superior sensitivity and boosted resolution.

Experimental
Instruments
The wielded Liquid chromatography facility was a Thermo
Fisher UPLC. Its model is Ultimate 3000—Complete Ultra

Performance Liquid Chromatography (USA). Separation
was done on Symmetry® Acclaim™ C18 column with dimensions (100 mm, 2.1 mm, 2.2 µm) (USA). Diode Array UV
Detector (DAD-3000 RS, USA) and an autosampler (WPS3000TRS, Thermo scientific USA) were employed. Solvent
degassing was utilized using Elmasonic S 60 H water bath
sonicator (Germany). To adjust pH, Jenway digital pH meter,
UK was used.

Chemicals and Reagents
High grades of DAPA propanediol monohydrate powder
guaranteed to contain 99.90% of pure raw material drug
were purchased from BaoJi Guokang Bio-technology co.,
Ltd. Metformin hydrochloride, certified to have 99.88% of
the active material of the drug, was kindly granted from
‘Chemical Industries Development’ (CID) Co. (Cairo,
Egypt). Xigduo X
 R® tablet contains 1000 mg MET and
5 mg DAPA was obtained from USA market. HPLC grade
methanol, acetonitrile and orthophosphoric acid (85%) were
obtained from Fisher Scientific (Loughborough, Leicestershire, UK). Ultrapure grade of potassium phosphate
monobasic was bought from Sigma-Aldrich (Deisenhofen,
Germany). Deionized and distilled water were provided in
house. Mobile phase was filtered through PTFE membrane
filters (UK) with diameter 47 mm and pore size of 0.20 mm.
Chemicals of analytical laboratory grade were used unless
marked differently.

Chromatographic Conditions
Separation was carried out using a S
 ymmetry® Acclaim™
C18 column (100 mm, 2.1 mm, 2.2 µm) via isocratic elution. Potassium phosphate monobasic as buffer (0.05 M)
with pH (3.5) and acetonitrile in (50:50, v/v) ratio was prepared as mobile phase. Wavelength of 225 nm was elected
for determination of both DAPA and MET. After preparation
of buffer, it was filtered using a 0.2-mm membrane filter then
degassing for 20 min. The pump was adjusted to deliver
mobile phase with 0.4 mL/min flow rate. Temperature of
column oven was maintained at 60 °C. Autosampler was set
to inject 10 µl of each sample each time. Typical separation
chromatogram is represented in Fig. 2.

Procedures
Preparation of Calibration Standards
Stock solutions of DAPA and MET with concentration of
1 mg/mL were solely prepared in methanol. Then working
solutions were obtained by dilution of the analogous stock
solutions with mobile phase. Both working solutions and
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Fig. 2  Chromatogram of laboratory prepared mixture of 60 µg of MET and 10 µg of DAPA under the mentioned conditions “Method Development”

initial stock solutions were stored at 4 °C in refrigerator and
shed within 30 days.
Calibration Curves Development
Aliquots between 1 and 50 µg for DAPA and 0.5–100 for µg
MET were separately and precisely taken from their working solutions into 10 mL volumetric flasks. Volumes were
completed to the final mark using mobile phase; potassium
phosphate monobasic: acetonitrile (50:50, v/v) pH 3.5. Final
ranges of concentration were: 1–50 µg/mL for DAPA and
0.5–100 µg/mL for MET. 10 µL of each concentration was
injected utilizing the mentioned conditions into the chromatographic system. Each injection is done in triplicates.
Plotting the value of area under the peak obtained for each
sample versus its comparable concentrations, calibration
curve was obtained for each drug. Consequently, regression
equations were computed.
Assay of Laboratory Prepared Mixtures
To prepare binary mixtures with different ratios, accurately
calculated volumes of DAPA and MET working solutions
were properly mixed. 10 µL of each mixture were injected
onto stationary phase. Percentage recoveries were then estimated using the corresponding regression equations.
Application to Pharmaceutical Preparation
Ten tablets of Xigduo X
 R® 5 mg DAPA/1000 mg MET were
solely weighed, powdered and thoroughly blended. Specific
amount of the obtained powder contains 100 mg of MET and
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0.5 mg of DAPA were dissolved in 30 mL of methanol in
100 mL volumetric flask, sonicated for 20 min. The solution
was filtered and made up to mark with mobile phase. This
step accompanied with spiking of precise calculated amount
of DAPA pure drug to achieve standard addition technique.
Standard addition technique is critical in this experiment,
as concentration ratio in dosage form is 1:200 DAPA to
MET which is out of the calibration that was made earlier
for DAPA. Hence, calculated pure amount was added to each
sample of DAPA, to guarantee its precise overall determination. First, analysis of 0.5:100, DAPA:MET out of dosage
form flask was carried out for MET determination, thereafter
a known amount of pure standard of DAPA was added making the final concentration within calibration range. Finally,
aliquots of 10 µl were injected on C18 stationary phase. Precise calculation of the different concentrations was done via
the corresponding regression equations as mentioned under
“Calibration Curves Development”. Data of sample enrichment and standard addition technique showed in Tables 3
and 4. Figure 3 represents a chromatogram of tablet extract,
100 µg of MET and 5.5 µg DAPA (0.5 µg of DAPA tablet
enriched with 5 µg of pure DAPA).
Stress Degradation Conditions of DAPA
Forced degradation studies of bulk drug included appropriate solid state and solution state were done in accordance
with the ICH regulatory guidance [36]. Prior to injection,
samples were withdrawn at appropriate time, neutralized (in
case of acid and alkali hydrolysis) and the solutions were
diluted with acetonitrile or mobile phase.
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Table 3  Statistical comparison
between the proposed UHPLC
method and the reported one
for the analysis of dapagliflozin
[5] and metformin [28] in pure
form

Item

Mean* ± SD
% RSD
n
Variance
t test**(2.262)
F test (6.2561)

Dapagliflozin

Metformin

Proposed

Reported

Proposed

Reported

99.72 ± 0.94
0.94
5
0.88
0.5408
4.363

100.04 ± 0.45
0.45
3
0.20

99.79 ± 0.51
0.51
5
0.26
2.097
2.522

100.59 ± 0.81
0.81
6
0.66

SD standard deviation, % RSD percent relative standard deviation

**

Values in parenthesis are the theoretical values of t and F at P = 0.05 [35]

For DAPA alkaline and acidic hydrolysis, accurately
weighed amount of 5 mg of drug was treated separately in
a 25-mL volumetric flask with certain volumes of 0.1 M,
0.5 M and 1 M sodium hydroxide to make final concentration of 200 µg/mL. The same was done for acidic conditions
with 0.1 M, 0.5 M and 1 M hydrochloric acid. The solutions
were heated in thermostatic water bath at 70 °C for successive time intervals 5, 10, 15, 20, 30, 60 and 120 min and then
1 mL from each solution was taken into 10 mL volumetric
flask and neutralized with pre-calculated volumes of acid
and base (hydrochloric acid and sodium hydroxide), respectively. Then complete to final volume with mobile phase
for acidic conditions and with acetonitrile in case of basic
degradation to prevent salting out of the phosphate buffer
used in mobile phase. Final concentrations of 20 µg/mL of
DAPA were obtained in each flask.
For thermal degradation, an accurately weighed amount
of 5 mg of DAPA solid powder was treated and heated for
72 h at 60 °C followed by cooling, dissolution and further
dilution to 20 µg/mL. Then it was injected on the stationary
phase.
For oxidative degradation, an accurately weighed amount
of 5 mg of DAPA treated separately with 6% and 30% (v/v)
hydrogen peroxide to reach final concentrations of 3% and
15% (v/v) after dilution, respectively. The prepared mixtures
were kept at room temperature for 12 and 5 h, respectively.
Thereafter, 10 microliters of the resultant solutions were
injected onto column and the chromatograms were run as
described before.
The photochemical degradation of the drug was also studied by exposing the dry powder to UV light of 8 W power
for 24 h. Powder was then dissolved and diluted with mobile
phase. Then 10 microliters of the resultant solutions were
injected onto column and the chromatograms were run as
described before. Similar to acidic and basic degradation,
the final concentration was elected via dilution with mobile
phase to reach optimum concentration of 20 µg/mL before
applying the chromatographic separations.

Method Validation
The validation of the proposed method has included linearity, accuracy, precision, and specificity, limits of detection
and quantification and robustness according to the procedures recommended by ICH Q2 (R1) [34].

Results and Discussion
The main aim of this work was to establish and validate
UHPLC–UV method for the simultaneous estimation of
DAPA and MET, accompanied with a stability monitoring
degradation study for DAPA under different stress conditions followed by kinetic study. Concerning the stability
indicating study; the current International Conference on
Harmonization (ICH) guidelines necessitate that stability
indicating assay methods should be performed and validated
over applying stress testing on the drug under different conditions, including hydrolysis at various pHs, oxidation and
thermal degradation [36].

Method Development
During the optimization cycle, several chromatographic conditions were attempted using C18 column (100 mm, 2.1 mm,
2.2 µm) Symmetry® Acclaim™ RSLC 120. Various mobile
phase compositions such as methanol with water, or acetonitrile with water, in different proportions were tried in an
isocratic mode. Then buffer was tried in different molarities
and ratios with either of methanol or acetonitrile. Initially,
0.03 M phosphate buffer used yet it gave no separation, so
higher molarity of 0.05 M was then considered and implemented. Acetonitrile accompanied with phosphate buffer of
0.05 M in (50:50, v/v) at a flow rate of 0.4 mL/min gave
sufficient separation and good resolution in isocratic mode
between the two drugs. In addition, it gave an optimum resolution of the two peaks of DAPA and its main degradation
product. Photodiode array detector (PDA) was set at 225 nm
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0.5

(1:200)**

100

5.0
4.0
7.0
10.0
20.0

Ratio present in Xigdue X
 R® tablets

99.94
100.44
100.09
100.31
100.54

5.50
4.50
7.50
10.50
20.50

Conc. (µg.mL−1)

Conc. (µg.mL−1)

DAPA

MET

Spiked DAPA

Added DAPA

Taken concentration (µg.
mL−1)

Average of three different determinations

**

*

Recovery%

60.0
5.0
50.0
100.0
80.0

5.0
2.5
25.0
10.0
20.0

Xigdue XR

DAPA

MET

DAPA
98.47
100.26
98.89
100.76
100.68
99.81 ± 1.16
1.16
1.35

Recovery

Concentration (µg mL−1)

Laboratory prepared mixtures

% RSD percent relative standard deviation, SD standard deviation

Mean* ± SD
% RSD
Variance

Item

Mean* ± SD
% RSD
Variance

Item

100.03
100.07
100.01
100.10
100.48

Recovery%

100.93
98.16
98.82
98.46
98.08
98.89
1.18
1.39

100.0
90.0
80.0
75.0
50.0

Tablet recov- MET
ery% after
subtraction
Taken conc
(µg.mL−1)

101.65
101.76
101.26
99.19
98.43
100.46 ± 1.54
1.54
2.37

MET

99.45
98.51
101.19
100.72
99.73
99.92
1.06
1.12

Recovery%

Table 4  Determination of dapagliflozin and metformin in laboratory prepared mixtures and in Xigdue XR tablets (application of standard addition technique) by the proposed method
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Fig. 3  Chromatogram of tablet extract of Xigdue XR® 100 µg of MET and 5.5 µg DAPA under the mentioned conditions “Method Development” (0.5 µg of DAPA tablet enriched with 5 µg of pure DAPA)

to obtain sufficient peak intensity for both two drugs and
DAPA degradation product. A typical chromatogram with
sufficient resolution is obtained; MET retention time was
at 0.9 min while DAPA was obtained at 1.5 min. The early
elution of metformin was due to its polar structure in comparison to dapagliflozin over the reversed phase stationary
phase (C18 column).
In sum, our method is efficient and simple to use, if compared with the previously reported methods. Moreover, this
is the only method utilizing UHPLC–UV for simultaneous
determination of DAPA and MET either in bulk or dosage
form.
In addition, stability study for DAPA was carried out
under diverse stress conditions (implementing ICH guidelines and optimized conditions from the literature) of heat,
UV light, oxidation with hydrogen peroxide and under different pH ranges from highly acidic to highly basic. The
presently developed method was also applied to the simultaneous separation of the main degradation product of DAPA
and DAPA itself.
The alkaline degradation study, which the kinetic study
was also applied, was the most effective one on the drug
substance of DAPA. The kinetics of the degradation reaction
was carefully monitored with different molarities of sodium
hydroxide and various time intervals at constant temperature
of 70 °C degrees. The main degradation product was then
characterized by UPLC–MS/MS followed by a hypothesis of
the expected alkaline degradation product of DAPA.
Many advantages originate from the implementation of
UHPLC in this technique. The first advantage is the shorter
run time with good chromatogram resolution; this is due to
smaller column size. Flow rate used was 0.4 mL/min which
is the lowest flow rate used that results in the least solvent
consumption, therefore this method is efficient and cost
effective to be used in quality control laboratories.

Method Validation
Linearity
Under the optimum chromatographic conditions, DAPA and
MET were evaluated by analyzing six different concentrations of each drug in triplicates. Linear relationship between
the peak area ratios of each analyte and their corresponding
concentrations was established. The linearity ranges were
found to be 1–50 µg/mL for DAPA and 0.5–100 µg/mL for
MET, results of each calibration represented in Table 2.
Accuracy
The accuracy of the proposed method was assessed by examining five levels of standard solutions of the studied analytes,
each three times. The proposed method results were satisfactorily compared with those of reported method for MET
[28] and DAPA [5], the results obtained from the statistical analysis showed no significant difference between the
performances of the proposed and reference method using
Student’s t test and variance ratio F-test, results showed in
Table 2.
Precision
The intraday precision was estimated through triplicate analysis of three different concentrations of the analytes within
the same day. On the other hand, the interday precision was
achieved through analysis of three different concentrations
of the analytes on three successive days. The RSD values
were less than 2% proving that the method was precise. The
percentage relative standard deviations were calculated as
abridged in Table 2.
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Fig. 4  a Chromatogram of 20 µg DAPA and its acid degradation product at 70 °C after 30 min (under the mentioned conditions
“Method Development”). b Chromatogram of 20 µg DAPA and
its base degradation product at 70 °C after 30 min (under the men-

tioned conditions “Method Development”). c Chromatogram of 20 µg
DAPA and its oxidation degradation product at room temperature
(under the mentioned conditions “Method Development”)

Specificity

interferences including degradation products and substances
used during formulation. The proposed method was used
for the determination of DAPA and MET and for separation

Specificity is the capability of the analytical method to
determine the analyte response when accompanied with
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Fig. 5  Degradation pattern of 20 µg DAPA by 0.5 M NaOH at 70 °C, ▸
over time intervals of 5, 10, 20, 60,120 min. The main degradation product retention time was 0.5 and the remaining dapagliflozin
appeared at retention time of 1.0 min under the mentioned conditions
“Method Development”

between DAPA and its main degradation product. The chromatograms of the samples were monitored for the detection
of any extra peaks, however, no chromatographic interference from any of the excipients was observed at the retention
times of the drugs. Moreover, the chromatogram of each
analyte in the sample solution was completely matching
with the chromatogram received from the standard solution. These results revealed the absence of interference from
any ingredient in the dosage form and therefore approve
the specificity of the proposed method, specificity results
showed in Table 2.
Limit of Detection (LOD) and Limit of Quantification (LOQ)
The LOD was taken as the amount for which the S/N ratio
was 3:1, while the LOQ was taken as the amount for which
the S/N ratio was 10:1. The results are shown in Table 2.
Robustness of the Method
Robustness was verified by changing slightly some parameters of the chromatographic conditions with no effect on
the resolution factor within two adjacent peaks (DAPA,
MET and DAPA with its degradation product). The flow
rate was changed by ± 0.1 mL/min. The wavelength was
altered ± 2 nm, while the pH was changed by ± 0.2 unites. It
was found that the suggested method is robust against these
changes.

Application of the Method for Analysis
of Laboratory Prepared Mixture and Dosage Form
The proposed method was effectively applied for the analysis
of laboratory prepared binary mixtures of DAPA and MET
in which the drugs were mixed in different ratios. The average percent recoveries were established on the average of
triplicate determinations as in Table 4.
Additionally, Xigduo X
 R ® tablets were analyzed to
show the capability of the proposed UHPLC–UV method
for routine analysis of the studied drugs in their formulation. As the ratio of two drugs in dosage form is out of the
calibration curve of DAPA, there was no way to determine
it without sample enrichment with known amount of its
pure form. Then by subtraction of the added pure concentration from the spiked concentration, the initial amount

13

W. A. Zaghary et al.

Degradation Behavior

Fig. 6  Full scan spectra of [M + H]+ of the basic degradation products of dapagliflozin

in tablet was found out. Moreover, this enrichment enables the study of the interference of commonly used tablet
excipients as it is a sort of standard addition technique.
Meanwhile, there was no need for addition of pure MET to
sample as its tablet concentration was within its calibration
range. Yet, MET recovery was determined for each dosage form sample along with DAPA, and it was excellent.
The concentrations of the two drugs were calculated referring to the corresponding regression equation. The mean
percentage recoveries as well as the standard deviation
obtained from the standard addition method indicated a
good precision and accuracy for the proposed UHPLC–UV
method, as presented in Table 4.

This work presents the first kinetic stability study for
DAPA using different stress conditions then measuring the
rate of formation of degradates over time [37]. Values of
t1/2 and t 90 were calculated for the molecule after accurate
applying of each stress condition. The results showed initially the remarkable stability of DAPA before it degraded
over time intervals from 5 min to 2 h. This stability may be
referred to its glycoside scaffold, only the terminal sugar
was the part affected and detached over degradation.
It was found that DAPA was susceptible to acidic, alkaline and oxidative degradation but resistant to thermal and
ultraviolet effects (Fig. 4). However, it was highly susceptible to alkaline hydrolysis; the corresponding chromatographic degradation pattern at increasing time intervals is
depicted in Fig. 5.
The corresponding full MS scan spectrum in Fig. 6
shows a signal with highest relative abundance (compared
to other signals) of the molecular mass of the expected
main degradation product. The expected degradation pathway of DAPA and structure elucidation of the main degradates in alkaline conditions are represented in Scheme 1
in which we notice cleavage of the sugar part of the glycoside giving away hydroxyacetaldehyde moiety. This was
emphasized by the mass spectrum obtained from the solution suspected to alkaline degradation.
The deduced structure of the alkaline degradation product is confirmed to be of sugar origin owing to its early
elution which might be referred to its polar structure.
Table 5 represents examples of other reported degradation
studies of DAPA, which in turn reveals that the proposed
method is more advantageous due to lower concentration
of acid or base used in degradation, higher degradation
% coincides with the stated stress degradation % to be
20–80% besides other optimized chromatographic criteria
due to UHPLC technique.

Degradation Kinetics
The kinetics of alkaline degradation of DAPA was investigated through withdrawing different samples of the degradation solutions at different time intervals (5, 10, 15, 30, 60,
120 min). A regular decrease in the drugs concentrations
was detected with increasing time. When plotting the log
of remained drug concentration versus time, a linear relationship was observed with good correlation coefficients
(Fig. 7).
Pseudo-first-order is the term used when two reactants
are involved in the reaction but one of them is in such a
Scheme 1  Proposed basic degradation of dapagliflozin

13

Kinetic Degradation Study of Dapagliflozin Coupled with UHPLC Separation in the Presence of…
Table 5  Stress conditions applied by reported methods for dapagliflozin
Drug

Method

Dapagliflozin Acid hydrolysis

Base hydrolysis

Thermal
hydrolysis

Photo stability

Oxidative degradation

Conditions

% degraded

Proposed method

Heating with 0.1, 0.5, 1 M HCl at 70 °C for 120 min

Mohammad Yunoos
et al. [5]
Manasa Sanagapati
et al. [8]
Proposed method

Reflux with 2 M HCl at 60 °C for 30 min

21% using 1M
HCl
7.49

Heating with 2 M HCl at 60 °C for 30 min

7.4

Heating with 0.1, 0.5, 1 M NaOH at 70 °C for 120 min
Reflux with 2 M NaOH at 60 °C for 30 min

88% using 0.5M
NaOH
6.37

Heating with 2 M NaOH at 60 °C for 30 min

6.4

Heating at 60 °C for 72 h
By refluxing on a water bath for 6 h at 60 °C

21%
4.99

Heating at 105 °C for 6 h

4.4

Exposing powder to UV for 24 h
Exposing powder to UV

No degradation
1.74

Exposing powder to UV for about 7 days

1.4

Drug was treated with 3% and 15% (v/v) H2O2 at room temperature
Drug was treated with 20% H2O2 (v/v) at 60 °C for 30 min

68% after 12 h

Drug was treated with 20% H2O2 (v/v) at 60 °C for 30 min

5.1

Mohammad Yunoos
et al. [5]
Manasa Sanagapati
et al. [8]
Proposed method
Mohammad Yunoos
et al. [5]
Manasa Sanagapati
et al. [8]
Proposed method
Mohammad Yunoos
et al. [5]
Manasa Sanagapati
et al. [12]
Proposed method
Mohammad Yunoos
et al. [5]
Manasa Sanagapati
et al. [8]

t1∕2 =

t90 =

Fig. 7  Pseudo-first order kinetic plot of: a the acidic degradation of
DAPA (20 µg/mL) at 70 °C using 1M HCl and b basic degradation of
DAPA (20 µg/mL) at 70 °C using 0.5 M NaOH

large excess that any change in its concentration is negligible compared with the change in the concentration of the
other reactant (drug). Rate constant (K), time left for 50%
potency (t1/2) and time left for 90% potency (t90) under alkaline stress condition were calculated using the following
equations [37]:
[ ]
log C0 − Kt
[ ]
(1)
Log Ct =
2.303

0.693
,
K
0.105
,
K

5.66

(2)
(3)

where K is the rate constant, [C0] is the concentration of
DAPA at time t = 0 and [Ct] is its concentration at time t.
The calculated K per minute, t1/2 and t90 values are shown in
Table 6 under various stress degradation conditions.
Stressful degradation was observed under alkaline
hydrolysis conditions for DAPA at 0.5N NaOH, where the
K value was found to be the highest compared with acidic
and oxidative degradations. On contrary, both t1/2 and t90
at alkaline conditions were found to be lower than those of
other conditions.
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Table 6  The calculated kinetic values of DAPA degradation under various stress conditions
Condition

Alkaline degradation
0.1 N

Acid degradation
0.5 N 1.0 N

0.1 N

Value
K per minute No quantitative degradation 0.023 Complete degradation No quantitative degradation
29.39
t1/2 (min)
4.454
t90 (min)

Conclusion
A novel, simple and specific stability-indicating
UHPLC–UV method was developed for the simultaneous
determination of dapagliflozin (DAPA) and metformin
(MET) in pharmaceutical dosage forms followed by studying DAPA degradation under different stress conditions.
Degradation reaction kinetics was investigated in addition
to structural elucidation of the main degradation product.
The utilization of UHPLC has enabled the use of a short
column with small particle size which resulted in uniform
chromatographic peaks within a very short run time. In addition, the low flow rate applied in this method has offered less
solvent consumption which is considered to be cost effective
and eco-friendly.
The method was validated in accordance with ICH
guidelines. The results gained from the validation study
have confirmed that the new method is selective, linear,
precise and accurate. Moreover, for the first time, degradation kinetics of DAPA was studied, proving that degradation was a pseudo-first-order reaction, and it was concluded that DAPA was extensively degraded under basic
conditions. Based on all previous advantages and results,
the developed method could be conveniently used in quality control laboratories.
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